Awards to the Institution

Award Value
Early Translational IV: Dan Gazit Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,180,674
Disease Team Therapy Planning I: Dan Gazit Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. $107,622
Research Leadership: Barry Stripp Epithelial progenitors and the stromal niche as therapeutic targets in lung disease $4,841,830
Disease Team Therapy Planning I: Clive Svendsen Stem Cells Secreting GDNF for the Treatment of ALS $63,487
Basic Biology V: Paul Noble Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $624,816
Disease Team Therapy Development - Research: Clive Svendsen Progenitor Cells Secreting GDNF for the Treatment of ALS $16,961,287
Disease Team Planning: Eduardo Marbán {REDACTED} Heart Disease Regenerative Medicine Team Planning Award $38,980
iPSC Consortia Award: Clive Svendsen The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development $300,000
Early Translational II: Dan Gazit Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
Transplantation Immunology: Terrence Town Role of HLA in neural stem cell rejection using humanized mice $1,119,385
Basic Biology IV: Eduardo Marbán Mechanism of heart regeneration by cardiosphere-derived cells $1,367,604
Disease Team Research I: Eduardo Marbán Autologous cardiac-derived cells for advanced ischemic cardiomyopathy $5,560,232
Late Stage Preclinical Projects: Shaomei Wang IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
New Faculty Physician Scientist: Robert Baloh Human iPSC modeling and therapeutics for degenerative peripheral nerve disease $3,031,737
Tools and Technologies II: Clive Svendsen Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. $1,933,022
Icon for xls export